Boule Diagnostics AB (CHIX:BOULS) Additional Paid-In Capital: kr336.2 Mil(As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:BOULS Boule Diagnostics AB CHIX:BOULS
41 GF Score
Price kr26.30
GF Value kr53.01
! 2 Warning Signs
View Full Analysis

What is Boule Diagnostics AB Additional Paid-In Capital?

Boule Diagnostics AB CHIX:BOULS 41 Additional Paid-In Capital is kr336.2 Mil as of Jun. 2026. GuruFocus rates CHIX:BOULS with a GF Score™ of 41/100 and a GF Value™ of kr53.01. The stock has 2 warning signs investors should review.


Boule Diagnostics AB's quarterly additional paid-in capital declined from Dec. 2025 (kr336.2 Mil) to Mar. 2026 (kr336.2 Mil) but then stayed the same from Mar. 2026 (kr336.2 Mil) to Jun. 2026 (kr336.2 Mil).

Boule Diagnostics AB's annual additional paid-in capital stayed the same from Dec. 2023 (kr336.2 Mil) to Dec. 2024 (kr336.2 Mil) and stayed the same from Dec. 2024 (kr336.2 Mil) to Dec. 2025 (kr336.2 Mil).

Boule Diagnostics AB Additional Paid-In Capital Related Terms

Boule Diagnostics AB Additional Paid-In Capital Historical Data

* Premium members only.

The historical data trend for Boule Diagnostics AB's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Boule Diagnostics AB Additional Paid-In Capital Chart

Boule Diagnostics AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 202.39 336.76 336.20 336.20 336.20

Boule Diagnostics AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 336.20 336.20 336.20 336.20 336.20
CHIX:BOULS
41GF Score
Boule Diagnostics AB CHIX:BOULS
Additional Paid-In Capital is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Boule Diagnostics AB Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)
What does a Additional Paid-In Capital of kr336.2 Mil mean?
Boule Diagnostics AB (CHIX:BOULS) has a Additional Paid-In Capital of kr336.2 Mil as of Jun. 2026. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Boule Diagnostics AB and its competitors.
Is Boule Diagnostics AB's Additional Paid-In Capital too high?
Boule Diagnostics AB's current Additional Paid-In Capital is kr336.2 Mil. Overall, Boule Diagnostics AB has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Boule Diagnostics AB's Additional Paid-In Capital compare to ABT and SYK?
Boule Diagnostics AB's Additional Paid-In Capital of kr336.2 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Additional Paid-In Capital for a Medical Devices & Instruments company?
A good Additional Paid-In Capital depends on the Medical Devices & Instruments industry context. However, Additional Paid-In Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Additional Paid-In Capital mean?
A high Additional Paid-In Capital can signal that a stock is expensive relative to its fundamentals. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Boule Diagnostics AB and its competitors. Boule Diagnostics AB's current Additional Paid-In Capital is kr336.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boule Diagnostics AB stock overvalued right now?
Boule Diagnostics AB (CHIX:BOULS) has a current Additional Paid-In Capital of kr336.2 Mil. The stock's GF Value™ is kr53.01, compared to a current price of kr26.30 — trading 50.4% below its estimated fair value. The current Additional Paid-In Capital is kr336.2 Mil. Boule Diagnostics AB's overall GF Score™ is 41/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Additional Paid-In Capital calculated?
Additional Paid-In Capital is calculated from a company's financial statements. For Boule Diagnostics AB (CHIX:BOULS), the current Additional Paid-In Capital is kr336.2 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Boule Diagnostics AB (CHIX:BOULS) Overvalued in 2026?

Based on GuruFocus' analysis, Boule Diagnostics AB stock appears to be undervalued. The current stock price of kr26.30 is trading 50.4% below its estimated GF Value™ of kr53.01.

Key valuation signals for CHIX:BOULS:

  • Additional Paid-In Capital: kr336.2 Mil
  • GF Value™: kr53.01 vs. price of kr26.30 (50.4% below fair value)
  • GF Score™: 41/100 with 2 warning signs

No single metric tells the full story. See the CHIX:BOULS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Boule Diagnostics AB Business Description

Other Exchanges BOUL:Sweden
Address Fagerstagatan 7, Spanga, SWE, SE-163 53
Boule Diagnostics AB is a company operating in the diagnostics market. It is engaged in the development, manufacturing and marketing instruments and consumables for blood diagnostics. The systems are intended for small and medium-sized hospitals, clinics and laboratories within outpatient care. the company operating through two complementary business segments: Diagnostics and OEM CDS. Through its subsidiaries, the company operates in USA ,Asia, Eastern Europe, Latin America Western Europe and Africa / Middle East. The majority revenue is generated from Asia.
41GF Score

Get the complete analysis for CHIX:BOULS

Additional Paid-In Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr26.30
Price
kr53.01
GF Value